No, Ivermectin and Mebendazole Do Not Cure Cancer
Ivermectin and mebendazole are FDA-approved antiparasitic medications with no established role in cancer treatment, and their use for cancer should be strongly discouraged outside of properly designed clinical trials. These drugs are approved exclusively for parasitic infections—ivermectin for strongyloidiasis and onchocerciasis 1, and mebendazole for pinworm, whipworm, roundworm, and hookworm infections 2.
Why This Matters for Patient Safety
The claim that these antiparasitics "cure cancer" is not supported by any high-quality clinical evidence and poses serious risks:
The Evidence Gap is Critical
- No FDA approval exists for cancer treatment with either drug 1, 2
- No large-scale randomized controlled trials have demonstrated anticancer efficacy in humans 3
- The most prominent recent study claiming benefit 4 has been issued an official Expression of Concern by the journal due to serious concerns about data verifiability, statistical reliability, and lack of proper ethical oversight 5
Preclinical Data Does Not Equal Clinical Benefit
While laboratory studies show these drugs can affect cancer cells in petri dishes and animal models 6, 7, this represents a massive translational gap. The overwhelming majority of drugs showing preclinical anticancer activity fail in human trials. Preclinical promise does not justify clinical use.
Real Harms from Misinformation
Patients pursuing unproven treatments may:
- Delay or abandon proven therapies (surgery, chemotherapy, radiation, immunotherapy) that could save their lives
- Experience dose-dependent toxicity, particularly gastrointestinal effects 4
- Suffer drug interactions, including increased bleeding risk when ivermectin is combined with warfarin 1
- Face severe neurological complications in certain populations, particularly those with Loa loa co-infection 1
What the Guidelines Actually Say
Current cancer treatment guidelines from major oncology organizations make zero mention of ivermectin or mebendazole as therapeutic options:
- Lung cancer guidelines 8, 9 recommend targeted therapies for driver mutations, immunotherapy, and platinum-based chemotherapy
- Melanoma guidelines 10, 11, 12 recommend surgery, immunotherapy (ipilimumab, pembrolizumab), and targeted therapy (vemurafenib for BRAF mutations)
- Breast cancer guidelines 13 recommend surgery, chemotherapy, endocrine therapy, and HER2-targeted agents
- Bladder cancer guidelines 14 recommend platinum-based chemotherapy and checkpoint inhibitors
None of these evidence-based guidelines include antiparasitic drugs.
The Only Legitimate Cancer-Related Use
The sole appropriate oncologic context for these drugs is palliative management of myiasis (maggot infestation) in fungating malignant wounds, where ivermectin combined with albendazole and clindamycin can rapidly clear larval burden 15. This treats a complication, not the cancer itself.
How to Counsel Patients
When patients ask about these drugs for cancer:
- Acknowledge their concern about finding effective treatments
- Clearly state these drugs are not proven cancer treatments and lack regulatory approval for this use
- Explain the risk of delaying proven therapies that could extend survival or achieve cure
- Redirect to evidence-based options appropriate for their specific cancer type and stage
- Offer clinical trial enrollment if standard options are exhausted, ensuring proper oversight and informed consent
The Bottom Line
The absence of clinical evidence is not a gap to be filled by hope—it is a warning. While research into drug repurposing is scientifically valid 6, 3, 7, the pathway from laboratory to clinic requires rigorous human trials demonstrating safety and efficacy. Until such evidence exists, recommending or condoning ivermectin and mebendazole for cancer treatment violates the fundamental principle of evidence-based medicine and potentially harms patients by diverting them from proven therapies.